Table 1.
Summary statistics of clinical and demographic characteristics
|
Active
Bleeding |
P Value | ||
|---|---|---|---|
| Yes | No | ||
| Age, yr | 40 | 55 | |
| Median (range) | 61.6 (23.9–82.1) | 61.1 (20.3–86.9) | |
| Gender, n (%) | |||
| Male | 24 (60.0) | 23 (41.8) | |
| Female | 16 (40.0) | 32 (58.2) | |
| Ethnicity, n (%) | |||
| White | 29 (72.5) | 42 (76.4) | |
| Black | 6 (15.0) | 7 (12.7) | |
| Hispanic | 3 (7.5) | 5 (9.1) | |
| Asian | 2 (5.0) | 1 (1.8) | |
| Basal malignancy, n (%) | |||
| Lung | 20 (50.0) | 26 (47.3) | |
| Metastatic cancer | 20 (50.0) | 29 (52.7) | |
| Smoking, n (%) | |||
| Positive | 7 (17.5) | 15 (27.3) | |
| Negative | 33 (82.5) | 40 (72.7) | |
| Heart disease, n (%) | |||
| No | 25 (62.5) | 27 (49.1) | |
| Yes | 15 (37.5) | 28 (50.9) | |
| Lung disease, n (%) | |||
| No | 19 (47.5) | 23 (41.8) | |
| Yes | 21 (52.5) | 32 (58.2) | |
| Kidney disease, n (%) | |||
| No | 38 (95.0) | 52 (94.5) | |
| Yes | 2 (5.0) | 3 (5.5) | |
| Liver disease, n (%) | |||
| No | 39 (97.5) | 54 (98.2) | |
| Yes | 1 (2.5) | 1 (1.8) | |
| Radiation therapy to chest, n (%) | |||
| No | 27 (67.5) | 37 (67.3) | |
| Yes | 13 (32.5) | 18 (32.7) | |
| Antiplatelet therapy, n (%) | |||
| No | 32 (80.0) | 45 (81.8) | |
| Yes | 8 (20.0) | 8 (14.5) | |
| Anticoagulant therapy, n (%) | |||
| No | 38 (95.0) | 52 (94.5) | |
| Yes | 2 (5.0) | 2 (3.6) | |
| Hemoglobin, g/dl | 0.124* | ||
| n | 38 | 48 | |
| Mean (SD) | 11.5 (1.8) | 12.1 (2.1) | |
| PTT | 0.466* | ||
| n | 37 | 49 | |
| Mean (SD) | 28.4 (3.4) | 29.0 (4.0) | |
| INR | 0.103† | ||
| n | 37 | 50 | |
| Median (range) | 1.1 (0.8–1.5) | 1.1 (0.8–3.3) | 0.103† |
| Platelets | |||
| n | 38 | 50 | |
| Mean (SD) | 320.1 (136.9) | 277.2 (107.3) | |
| Median | 288.5 | 273.5 | |
| Creatinine, mg/dl | 0.060† | ||
| n | 38 | 52 | |
| Median (range) | 0.9 (0.5–1.8) | 1.0 (0.5–2.3) | |
| Time from hemoptysis onset to consultation, d | 0.265† | ||
| n | 40 | 54 | |
| Median (range) | 14.0 (1.0–180.0) | 14.0 (1.0–150.0) | |
| Time from consultation to bronchoscopy, d | 0.073† | ||
| n | 40 | 55 | |
| Median (range) | 1.0 (0.5–7.0) | 1.0 (0.5–14.0) | |
| ECOG PS, n (%) | 0.197‡ | ||
| PS 0 | 3 (7.5) | 7 (12.7) | |
| PS 1 | 17 (42.5) | 32 (58.2) | |
| PS 2 | 13 (32.5) | 12 (21.8) | |
| PS 3 | 7 (17.5) | 4 (7.3) | |
| Resolved in 48 h, n (%) | 0.068‡ | ||
| No | 12 (30.0) | 8 (14.5) | |
| Yes | 28 (70.0) | 47 (85.5) | |
| Blood transfusion, n (%) | 0.229 | ||
| No | 35 (89.7) | 53 (96.4) | |
| Yes | 4 (10.3) | 2 (3.6) | |
| Endobronchial lesion, n (%) | <0.001§ | ||
| No | 10 (25.0) | 45 (81.8) | |
| Yes | 30 (75.0) | 10 (18.2) | |
| Stage, n (%) | 0.010‡ | ||
| Early | 3 (7.5) | 16 (29.1) | |
| Advanced | 37 (92.5) | 39 (70.9) | |
Definition of abbreviations: ECOG = Eastern Cooperative Oncology Group; INR = international normalized ratio; PS = performance status; PTT = partial thromboplastin time.
*
t Test.
†
Wilcoxon rank-sum test.
‡
Fisher’s exact test.
§
Pearson chi-square test.